BRAINBox Solutions reports near-completion of its HeadSMART II trial for a concussion blood test, supporting an upcoming FDA submission, and advances in a point-of-care biomarker collaboration with Prolight Diagnostics.
A study found that circulating tumor DNA testing detected residual disease signals missed by conventional prognostic measures in patients with breast cancer.
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
A proof-of-concept study shows that bacteria-metabolized molecules enriched with carbon-13 produce detectable exhaled CO2, enabling rapid infection identification with inexpensive infrared scanners.
The new panel includes 11 female-specific biomarkers covering hormonal transitions, thyroid function, and nutrient levels.
Researchers at JAX and MIT have developed a microneedle patch that samples immune cells from skin within hours, providing a noninvasive alternative to blood draws and biopsies.
The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
The newly identified aptamers match antibody-level binding strength and could support the development of lower-cost, point-of-care blood tests for neurodegeneration.
Researchers at UC San Diego have developed the MAPI score, a blood test using five standard lab values to distinguish alcohol-related liver injury from metabolic causes, according to a study in Gastroenterology.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Research in bone marrow transplant patients with blood cancers and febrile neutropenia suggests the host-response test may help identify infection in high-risk populations.